Is Canafenib available in China? How much does it cost per box?

Encorafenib (Encorafenib), trade name Braftovi, is an oral small molecule BRAF kinase inhibitor. The drug was approved by the U.S. Food and Drug Administration (FDA) in 2018 and is mainly used to treat patients with unresectable or metastatic melanoma carrying BRAF V600E or V600K mutations.

The mechanism of action of Canafenib is to reduce the growth and spread of tumor cells by inhibiting the abnormal signal transduction pathways caused byBRAF gene mutations. Clinically, canafenib is often used in combination with MEK inhibitors (such as binimetinib) to enhance the therapeutic effect. For certain patient populations, canafenib has also shown potential in the treatment of previously treated metastatic colorectal cancer harboring the BRAF V600E mutation.

The recommended dose of canafenib varies depending on the disease being treated. For patients with melanoma, the recommended dose is 450 mg once daily in combination with binimetinib; and for patients with colorectal cancer, the recommended dose is 300 mg once daily with Erbitux.

However, it is worth noting that canafenib is not yet on the market in China, and domestic patients cannot directly obtain this drug for the time being. At the same time, the use of canafenib may also be associated with some side effects, such as fatigue, nausea, vomiting, etc., but they are usually acceptable and controllable. Patients should understand the drug information in detail before use and proceed under the guidance of a doctor.

Canafenib is not currently on the market in China, and domestic patients currently have no way to directly obtain this drug. It is understood that Canafenib is available in Europe. There are two specifications of Canafenib available in Europe. The price of 75mg*42 tablets is around 17,000 yuan, and the price of 75*168 tablets is around 59,000 yuan. If the patient needs the drug Canafenib, please consult a regular overseas medical consultation to understand.